A Study of Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether erdafitinib is an effective treatment for
FGFR3-altered non-muscle invasive bladder cancer/NMIBC between the time that a recurrent
tumor is identified and a TURBT (transurethral resection of a bladder tumor) or biopsy
procedure is performed to remove it.